drugset / Trial / NCT00293371
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
Phase 1/2
Terminated
6 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving vatalanib together with docetaxel and prednisone may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of vatalanib when given together with docetaxel and prednisone and to see how well they work in treating patients with advanced prostate cancer.
Timeline
- Start
- 2005-02
- Primary completion
- 2006-09
- Completion
- 2006-09
Outcome
Outcome not reported
Stopped (Enrollment): “low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | vatalanib | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | Oral |